Treatment with recombinant human Gal-9 can induce macrophage differentiation into plasmacytoid DC-like macrophages (Mφs) in vivo, enhancing NK cell activation and prolonging the survival of mice with lung cancer [289]. Here, LGALS9 is linked to lung carcinoma.